
## Paul B Mullan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7889243/publications.pdf Version: 2024-02-01



**Ρ**ΛΙΙΙ R ΜΙΠΙΛΝ

#	Article	IF	CITATIONS
1	Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090604.	1.4	5
2	Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. Journal of Oncology, 2020, 2020, 1-10.	0.6	7
3	Identification and SAR exploration of a novel series of Legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1546-1548.	1.0	4
4	NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. BMC Cancer, 2019, 19, 236.	1.1	11
5	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. Oncotarget, 2019, 10, 4630-4639.	0.8	12
6	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
7	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 2018, 9, 4722-4736.	0.8	22
8	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
9	Flat SAR of P3-methylsulphonamide based small molecule legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 413-416.	1.0	6
10	Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). Oncotarget, 2016, 7, 55458-55472.	0.8	19
11	The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription. Oncotarget, 2016, 7, 68097-68110.	0.8	15
12	A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget, 2016, 7, 19884-19896.	0.8	30
13	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
14	Development of a potent and selective cell penetrant Legumain inhibitor. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5642-5645.	1.0	14
15	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Modern Pathology, 2015, 28, 428-436.	2.9	27
16	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget, 2015, 6, 43244-43254.	0.8	8
17	The gene regulatory network for breast cancer: integrated regulatory landscape of cancer hallmarks. Frontiers in Genetics, 2014, 5, 15.	1.1	74
18	Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt335.	3.0	91

PAUL B MULLAN

#	Article	IF	CITATIONS
19	P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2521-2524.	1.0	9
20	NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene, 2014, 33, 713-723.	2.6	41
21	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	1.6	59
22	BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 205-216.	3.3	25
23	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-I <sup>3</sup> -mediated apoptosis. Oncogene, 2005, 24, 5492-5501.	2.6	53